Drugs / Tocillizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04577534 | Aug 2020 → Jun 2021 | COVID-19 | Turku University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tocillizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04577534 ↗ |
| Known as | TCZ | “iv Tocillizumab (TCZ)” NCT04577534 ↗ |
| Route | Intravenous | “Participants will receive one infusion of iv TCZ (according to weight of patient)” NCT04577534 ↗ |